(0.04%) 5 471.67 points
(0.09%) 39 149 points
(0.35%) 17 780 points
(0.04%) $80.86
(-3.66%) $2.66
(-0.80%) $2 312.20
(0.16%) $28.92
(3.51%) $1 021.00
(0.28%) $0.936
(0.69%) $10.68
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases...
Stats | |
---|---|
今日成交量 | 43 238 |
平均成交量 | 59 537 |
市值 | 48.63M |
EPS | $-9.34 ( Q3 | 2023-11-09 ) |
下一个收益日期 | ( $0 ) 2024-08-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.162 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $2.39 (12.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-29 | Fairmount Funds Management Llc | Buy | 406 038 | Common Stock |
2023-12-29 | Fairmount Funds Management Llc | Sell | 3 435 480 | Common Stock |
2023-12-22 | Burrows Scott L | Buy | 134 953 | Common Stock |
2023-12-07 | Fairmount Funds Management Llc | Buy | 16 667 | Series B Preferred Stock |
2023-11-22 | Albers Jeffrey W. | Buy | 50 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-5.07 |
Last 85 transactions |
Buy: 64 136 392 | Sell: 71 129 759 |
音量 相关性
Aeglea Bio Therapeutics 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Aeglea Bio Therapeutics 相关性 - 货币/商品
Aeglea Bio Therapeutics 财务报表
Annual | 2022 |
营收: | $2.33M |
毛利润: | $2.33M (100.00 %) |
EPS: | $-24.86 |
FY | 2022 |
营收: | $2.33M |
毛利润: | $2.33M (100.00 %) |
EPS: | $-24.86 |
FY | 2021 |
营收: | $18.74M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.233 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.520 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。